These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 27440266)

  • 21. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
    Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N
    Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908
    [No Abstract]   [Full Text] [Related]  

  • 24. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.
    Altan M; Kidwell KM; Pelekanou V; Carvajal-Hausdorf DE; Schalper KA; Toki MI; Thomas DG; Sabel MS; Hayes DF; Rimm DL
    NPJ Breast Cancer; 2018; 4():40. PubMed ID: 30564631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines.
    Sun SQ; Jiang CG; Lin Y; Jin YL; Huang PL
    J Int Med Res; 2012; 40(2):497-506. PubMed ID: 22613410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
    [No Abstract]   [Full Text] [Related]  

  • 29. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
    Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
    Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of immune microenvironment in gastrointestinal stromal tumours.
    Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
    Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.
    Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C
    BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
    Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
    PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
    Hacking S; Vitkovski T; Jain S; Jin C; Chavarria H; Wu D; Nasim M
    Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):201-208. PubMed ID: 32842025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
    Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
    Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.
    Mizuno T; Kamai T; Tsuzuki T; Nishihara D; Kijima T; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2022 Mar; 71(3):565-578. PubMed ID: 34275008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B7-H3 and B7-H4 Expression in Breast Cancer and Their Association with Clinicopathological Variables and T Cell Infiltration.
    Kim NI; Park MH; Kweon SS; Lee JS
    Pathobiology; 2020; 87(3):179-192. PubMed ID: 32088722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.